Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Janssen-Ortho LLC Clear all
Completed Phase 3 Interventional Results available

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

NCT01094886
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions
Rivaroxaban
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Terminated Phase 3 Interventional Results available

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

NCT00516269
View directory record Official record
Conditions
Breast Cancer, Fatigue, Gastrointestinal Cancer
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Not applicable Interventional

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

NCT00845572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Consta Club
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

NCT00257010
View directory record Official record
Conditions
Migraine
Interventions
Almotriptan Malate
Drug
Lead sponsor
Janssen-Ortho LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Mobile, Alabama • Montgomery, Alabama • Oxford, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

NCT00539071
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

NCT00302458
View directory record Official record
Conditions
Healthy
Interventions
OROS-Methylphenidate, Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 28, 2026, 3:17 PM EDT
Terminated Phase 4 Interventional Results available

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

NCT00946985
View directory record Official record
Conditions
Schizophrenia
Interventions
paliperidone palmitate, oral risperidone
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

NINDS CRC Chronic Migraine Treatment Trial

NCT00772031
View directory record Official record
Conditions
Chronic Migraine
Interventions
propranolol LA, topiramate, placebo
Drug
Lead sponsor
Anne Lindblad
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

NCT00566735
View directory record Official record
Conditions
Major Depression, Bipolar Depression, Schizoaffective Disorder
Interventions
Razadyne, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

NCT01027897
View directory record Official record
Conditions
Sepsis
Interventions
Doripenem
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional

Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study

NCT00352196
View directory record Official record
Conditions
Asperger's Disorder
Interventions
Risperidone, Magnetic Resonance Spectroscopy
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
6 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 28, 2026, 3:17 PM EDT
Withdrawn Phase 4 Interventional

Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate

NCT00931398
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional

Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

NCT00203463
View directory record Official record
Conditions
PTSD
Interventions
topiramate
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Neuroimaging of the Effects of Concerta in the Treatment of ADHD

NCT00778310
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate-OROS, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
9 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

NCT00571688
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal (risperidone) Consta, Treatment as usual
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

NCT00535145
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Treatment as usual (TAU), Paliperidone ER
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
21
States / cities
Cerritos, California • Chino, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

Study of Paliperidone ER in Adolescents and Young Adults With Autism

NCT00549562
View directory record Official record
Conditions
Autism
Interventions
Paliperidone ER
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

NCT01134731
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
paliperidone, lithium, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians

NCT00208130
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Topiramate
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

Lab School Day Study for CONCERTA of Older Children With ADHD

NCT00799409
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo/ CONCERTA (methylphenidate HCl), CONCERTA (methylphenidate HCl) / Placebo
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
9 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Irvine, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 28, 2026, 3:17 PM EDT
Completed Phase 4 Interventional Results available

CONCERTA Lab School Study

NCT00799487
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CONCERTA (methylphenidate HCl) or placebo
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
9 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Little Rock, Arkansas • Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 28, 2026, 3:17 PM EDT